Implication of Micronized Purified Flavonoid Fraction

Implication of Micronized Purified Flavonoid Fraction (MPPF) for the treatment of the Chronic Venous Disease (CVD).

Chronic Venous Disease (CVD) is a progressive medical condition that results from venous hypertension and can lead to diminished venous integrity and function, varicose veins, chronic inflammation, leg swelling, or even skin alterations and ulceration. It is already a major and growing global medical problem, with a high economic burden. Although widespread, this condition is particularly evident in Western countries, where risk factors for Chronic Venous Disease (CVD) are prevalent, sedentary lifestyles and occupations are common, and obesity is escalating. Because advanced age is the most critical risk factor, and the age of the population continues to increase, the prevalence of Chronic Venous Disease (CVD), as well as the already substantial burdens of CVD-related morbidity, disability, and healthcare are all expected to increase in the coming decades. These alarming trends indicate an urgent need for treatments that can alleviate the symptoms of Chronic Venous Disease (CVD) and prevent its progression over time.

The roles of inflammation and endothelial dysfunction been properly assessed. Venoactive drugs present pharmacological and clinical profiles that can be explained by their action at specific levels of Chronic Venous Disease (CVD) pathophysiology. The pharmacological profiles and demonstrated clinical benefits of venoactive drugs provide the rationale behind their use in the treatment of Chronic Venous Disease (CVD). Micronized Purified Flavonoid Fraction (MPPF) increases venous contractility in isolated vein preparations and increases venous tone in persons at risk for varicose veins.

The effects of Micronized Purified Flavonoid Fraction (MPPF) have been demonstrated in both clinical and non-clinical studies, with reported improvements in venous tone and contractility, microcirculation, trophic disorders, and venous ulcer healing, and reductions in edema, vein inflammation, leukocyte adhesion and activation, and inflammatory mediator production. A recent meta-analysis of randomized, double-blind, placebo-controlled clinical trials investigating the effectiveness of Micronized Purified Flavonoid Fraction (MPPF) treatment in improving the symptoms, signs, and QOL in Chronic Venous Disease (CVD) patients.

However, Micronized Purified Flavonoid Fraction (MPPF) is recommended in international guidelines for the treatment of Chronic Venous Disease (CVD). It is the only phlebotonic with 1st recommendation in the treatment of venous ulcers. Micronized Purified Flavonoid Fraction (MPPF) is the only one to obtain a grade 1A (based on a strong recommendation for use and moderate quality of evidence) in the relief of symptoms associated with C0s to C6.